ACADIA Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.

Atai Beckley Inc. operates as a clinical-stage biopharmaceutical firm dedicated to the discovery, advancement, and commercialization of innovative therapeutic solutions for a variety of mental health conditions. The company's operations extend across the United States, Germany, and Canada. Its development pipeline features several key compounds: BPL-003: An intranasally administered formulation of mebufotenin benzoate salt, currently undergoing Phase 2a and 2b clinical trials for its potential in treating both treatment-resistant depression (TRD) and alcohol use disorder. RL-007: An orally active, pro-cognitive neuromodulator, progressing through a Phase 2b study focused on cognitive impairment associated with schizophrenia. ELE-101: A serotonergic psychedelic compound designed to address major depressive disorder. VLS-01: An oral transmucosal film featuring N,N-Dimethyltryptamine, which is in a Phase 2 clinical study for TRD. EMP-01: An orally administered form of R-3,4-methylenedioxy-methamphetamine, also in Phase 2 trials for social anxiety disorder. EGX-A & EGX-B: Non-hallucinogenic 5-HT2A receptor agonists, which are being explored for treatment-resistant depression. Beyond these pipeline assets, the firm also provides COMP360 for psilocybin therapy and GRX-917, aimed at treating anxiety, depression, and various neurological conditions. Originally known as Atai Beckley N.V., the entity officially changed its name to Atai Beckley Inc. in December 2025. Established in 2018, its corporate headquarters are situated in New York, New York.

Newron Pharmaceuticals S.p.A.NWRN · PharmaceuticalsBresso, Italy

69% matchPublic

Founded in 1999 and headquartered in Bresso, Italy, Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical enterprise focused on discovering and progressing therapeutic solutions. Its primary areas of research and development encompass conditions affecting the central and peripheral nervous systems, alongside pain management, with activities primarily conducted in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease and is also exploring its application for levodopa-induced dyskinesia. Furthermore, Newron is advancing Evenamide for various forms of schizophrenia, including those resistant to existing treatments, and Ralfinamide for the rare disease indication of neuropathic pain.

Supernus Pharmaceuticals, Inc.0LB2 · PharmaceuticalsRockville, United States

68% matchPublic

Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research, development, and market introduction of therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed medications addresses a range of CNS conditions. These include Trokendi XR, an extended-release formulation of topiramate used for managing epilepsy and preventing migraine headaches, and Oxtellar XR, an extended-release oxcarbazepine prescribed as a standalone treatment for partial-onset epileptic seizures in individuals aged 6 to 17 and adults. Another key offering is Qelbree, a selective norepinephrine reuptake inhibitor specifically designed for pediatric patients (ages 6 to 17) suffering from attention-deficit hyperactivity disorder (ADHD). For Parkinson's Disease (PD), Supernus provides APOKYN for acute intermittent treatment of 'off' episodes or hypomobility in advanced stages, XADAGO to aid patients on levodopa/carbidopa experiencing 'off' periods, and GOCOVRI to treat dyskinesia. Osmolex ER is also available for PD and drug-induced extrapyramidal reactions in adults. Furthermore, the company commercializes MYOBLOC, a Type B toxin, for treating cervical dystonia and sialorrhea in adult patients. Beyond its commercialized therapies, Supernus maintains an active pipeline of investigational treatments. This includes Qelbree (SPN-812), having finished Phase III trials for ADHD, and SPN-830, a late-stage drug/device combination aiming to prevent 'off' episodes in Parkinson's patients. Also in development are SPN-817, a novel compound undergoing Phase I clinical trials for severe epilepsy, and SPN-820, currently in Phase II for refractory depression. Additionally, two preclinical-stage candidates, SPN-443 and SPN-446, are being explored for other CNS indications. The distribution of these products occurs via pharmaceutical wholesalers, specialized pharmacies, and various distributors. Established in 2005, the company maintains its principal office in Rockville, Maryland.

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

BetterLife Pharma Inc., a biotechnology firm headquartered in Vancouver, Canada, specializes in researching and bringing to market therapeutic compounds designed to address neurological disorders across the globe. The company's core focus involves refining and advancing drug candidates derived from interferon-based technologies, which are intended to leverage the immune system to combat viral infections. Its diverse product pipeline includes BETR-001, targeting conditions such as major depressive disorder, treatment-resistant depression, cluster headaches, and post-traumatic stress disorder. Another candidate, BETR-002, is being developed for benzodiazepine dependency, anxiety, and spasticity. Furthermore, BetterLife Pharma is working on MM-003 for COVID-19 and other respiratory viral infections, MM-001 as a localized intravaginal cream for HPV-induced cervical intraepithelial neoplasia, and AP-002 for cancer treatment. The company also maintains a research collaboration with the University of California San Diego, conducting preclinical behavioral pharmacology studies on TD-0148A, a lysergic acid diethylamide derivative solution. Incorporated in 2002, the company operated as Pivot Pharmaceuticals Inc. before officially changing its name to BetterLife Pharma Inc. in December 2019.